Clinical Trials Logo

Hepatitis C Virus clinical trials

View clinical trials related to Hepatitis C Virus.

Filter by:

NCT ID: NCT02023112 Completed - Hepatitis C Virus Clinical Trials

Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection

GIFT-II
Start date: January 2014
Phase: Phase 3
Study type: Interventional

This is a Phase 3, randomized, open-label, multicenter study, enrolling non-cirrhotic and cirrhotic subjects. The purpose of this study is to evaluate the efficacy and safety of ABT-450/r/ABT-267 co-administered with weight-based RBV for 12 or 16 weeks in adult chronic HCV genotype 2-infected treatment-naïve and interferon (IFN) treatment-experienced subjects with and without compensated cirrhosis.

NCT ID: NCT02002767 Completed - Hepatitis C Virus Clinical Trials

Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment

Start date: December 16, 2013
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to evaluate the single-dose pharmacokinetics (PK) of velpatasvir (formerly GS-5816) in participants with severe renal impairment using matched healthy participants as a control group.

NCT ID: NCT01995071 Completed - Chronic Hepatitis C Clinical Trials

A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

Start date: November 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and antiviral effect of multiple doses of ABT-493 and ABT-530 in adults with genotype 1 HCV.

NCT ID: NCT01838590 Completed - Hepatitis C Virus Clinical Trials

Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection

Start date: March 2013
Phase: Phase 3
Study type: Interventional

This study is to to evaluate the safety, tolerability, and efficacy of sofosbuvir (SOF) plus ribavirin (RBV) in Egyptian adults with genotype 4 hepatitis C virus (HCV) infection.

NCT ID: NCT01741545 Completed - Hepatitis C Virus Clinical Trials

Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia

MAGNITUDE
Start date: March 31, 2013
Phase: Phase 3
Study type: Interventional

The primary objective for this study is to evaluate the proportion of subjects who achieve SVR12 (HCV RNA < LLOQ (target not detected) at post-treatment follow-up Week 12 in subjects with Genotype(GT)-1b, -4 and GT-2, -3

NCT ID: NCT01713283 Completed - Hepatitis C Virus Clinical Trials

Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection

Start date: October 2012
Phase: Phase 2
Study type: Interventional

This study is to evaluate the safety, tolerability, and antiviral activity of sofosbuvir (SOF) with ribavirin (RBV) in Egyptian adults with chronic genotype 4 hepatitis C virus (HCV) infection.

NCT ID: NCT01628692 Completed - Hepatitis C Virus Clinical Trials

Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus

Start date: July 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of daclatasvir and simeprevir with and without ribavirin for genotype 1 chronic hepatitis C virus infection in patients who are treatment-naive or null responders to previous pegylated interferon/ribavirin therapy.

NCT ID: NCT01605513 Completed - Hepatitis C Virus Clinical Trials

Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease

PEG-IFN-SA
Start date: June 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether PEG-IFN-SA is safe, tolerant and effective in the treatment of HCV patients.

NCT ID: NCT01598090 Completed - Hepatitis C Virus Clinical Trials

Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir

PEDESTAL
Start date: June 14, 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether Peginterferon Lambda-1a (Lambda) combined with Ribavirin (RBV) and Telaprevir (TVR) is effective in the treatment of chronic Hepatitis C (CHC) compared to Peginterferon Alfa-2a (alfa-2a) combined with RBV and Telaprevir.

NCT ID: NCT01581203 Completed - Hepatitis C Virus Clinical Trials

Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)

Hallmark DUAL
Start date: May 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to estimate efficacy, as determined by the proportion of subjects with Sustained virologic response at post-treatment Week 12 (SVR12), defined as Hepatitis C virus (HCV) Ribonucleic acid (RNA) < Limit of quantitation (LOQ) at post-treatment Week 12, for subjects who are prior null or partial responders to P/R or who are treatment-naive.